193 related articles for article (PubMed ID: 18312040)
41. Adherence to guidelines and treatment compliance in the Chilean national program for first-episode schizophrenia.
Markkula N; Alvarado R; Minoletti A
Psychiatr Serv; 2011 Dec; 62(12):1463-9. PubMed ID: 22193794
[TBL] [Abstract][Full Text] [Related]
42. Continuity of antipsychotic medication management for Medicaid patients with schizophrenia.
Farley JF; Wang CC; Hansen RA; Voils CI; Maciejewski ML
Psychiatr Serv; 2011 Jul; 62(7):747-52. PubMed ID: 21724787
[TBL] [Abstract][Full Text] [Related]
43. [Cannabis and schizophrenia: demographic and clinical correlates].
Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
45. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program.
Ahn J; McCombs JS; Jung C; Croudace TJ; McDonnell D; Ascher-Svanum H; Edgell ET; Shi L
Value Health; 2008; 11(1):48-56. PubMed ID: 18237360
[TBL] [Abstract][Full Text] [Related]
46. Adherence to Antipsychotic Medication by Community-Based Patients With Schizophrenia in China: A Cross-Sectional Study.
Wang X; Zhang W; Ma N; Guan L; Law SF; Yu X; Ma H
Psychiatr Serv; 2016 Apr; 67(4):431-7. PubMed ID: 26725294
[TBL] [Abstract][Full Text] [Related]
47. Survey of medication adherence in patients with schizophrenia--Korean ADHES data.
Kim SW; Yoon JS; Choi SK
Hum Psychopharmacol; 2006 Dec; 21(8):533-7. PubMed ID: 17133616
[TBL] [Abstract][Full Text] [Related]
48. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
49. Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia.
Morken G; Grawe RW; Widen JH
J Clin Psychiatry; 2007 Apr; 68(4):566-71. PubMed ID: 17474812
[TBL] [Abstract][Full Text] [Related]
50. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia.
Patterson TL; Lacro J; McKibbin CL; Moscona S; Hughs T; Jeste DV
J Clin Psychopharmacol; 2002 Feb; 22(1):11-9. PubMed ID: 11799337
[TBL] [Abstract][Full Text] [Related]
51. Course of adherence to medication and quality of life in people with schizophrenia.
Puschner B; Angermeyer MC; Leese M; Thornicroft G; Schene A; Kikkert M; Burti L; Tansella M; Becker T
Psychiatry Res; 2009 Feb; 165(3):224-33. PubMed ID: 19155070
[TBL] [Abstract][Full Text] [Related]
52. Use of a Web-Based Shared Decision-Making Program: Impact on Ongoing Treatment Engagement and Antipsychotic Adherence.
Finnerty MT; Layman DM; Chen Q; Leckman-Westin E; Bermeo N; Ng-Mak DS; Rajagopalan K; Hoagwood KE
Psychiatr Serv; 2018 Dec; 69(12):1215-1221. PubMed ID: 30286709
[TBL] [Abstract][Full Text] [Related]
53. Role of ethnicity in predicting antipsychotic medication adherence.
Opolka JL; Rascati KL; Brown CM; Gibson PJ
Ann Pharmacother; 2003 May; 37(5):625-30. PubMed ID: 12708934
[TBL] [Abstract][Full Text] [Related]
54. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample.
Chwastiak L; Rosenheck R; Leslie D
Med Care; 2006 Jan; 44(1):55-61. PubMed ID: 16365613
[TBL] [Abstract][Full Text] [Related]
55. Patient and Clinician Characteristics Associated with Adherence. A Cohort Study of Veterans with Incidental Pulmonary Nodules.
Moseson EM; Wiener RS; Golden SE; Au DH; Gorman JD; Laing AD; Deffebach ME; Slatore CG
Ann Am Thorac Soc; 2016 May; 13(5):651-9. PubMed ID: 27144794
[TBL] [Abstract][Full Text] [Related]
56. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence.
Dolder CR; Lacro JP; Warren KA; Golshan S; Perkins DO; Jeste DV
J Clin Psychopharmacol; 2004 Aug; 24(4):404-9. PubMed ID: 15232332
[TBL] [Abstract][Full Text] [Related]
57. Interventions to improve medication adherence in schizophrenia.
Zygmunt A; Olfson M; Boyer CA; Mechanic D
Am J Psychiatry; 2002 Oct; 159(10):1653-64. PubMed ID: 12359668
[TBL] [Abstract][Full Text] [Related]
58. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
[TBL] [Abstract][Full Text] [Related]
59. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
60. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial.
Chien WT; Mui JH; Cheung EF; Gray R
Trials; 2015 Jun; 16():270. PubMed ID: 26072311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
